BIO.RO Biofarm Bucure

Healthcare Drug Manufacturers - Specialty & Generic Bucharest Stock Exchange
1.37 RON
Close of Oct 30, 2026
0.6883 1.38
Market cap
RON 1.35B
P/E
19.6x
P/B
3.42x
ROE
13.5%
Dividend yield
2.17%
Fundamental score
3.2/5

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Jun 2026.

Is BIO.RO undervalued?

Graham number
Price1.37
Graham value0.7948
Premium72.4%

BIO.RO trades 72.4% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Biofarm Bucure fundamental analysis

16 of 22 checks passed

ROE 1/2

Moderate return on equity (13.5%), between 10% and 20%.

ROA 1/1

Return on assets (8.8%) is above the industry median (3.7%).

Profit Consistency 2/2

Profitable for 7 consecutive years.

Earnings Growth 5Y 1/1

Earnings per share grew over the past 5 years.

Earnings Acceleration 1/1

Last year's EPS growth (35.3%) is above the 5-year average (13.1% a year).

Earnings Growth vs Industry 1/1

Last year's EPS growth (35.3%) is above the industry median (24.7%).

Revenue Growth 1/2

Revenue grew 4.9% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (0.3%), 40% or less.

Debt Trend 0/1

Debt to equity has risen over the past 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 1/1

No interest expense reported.

PE vs Market 0/1

PE (19.6x) is above the market median (18.3x).

PE vs Industry 0/1

PE (19.6x) is above the industry median (19.0x).

PBV 0/1

Price to book (3.4x) is above the industry median (2.6x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 66.9, limit 22.5).

PEG 0/1

PEG on 5-year earnings growth is 1.49, above 1.

Dividend Yield 1/2

Dividend yield (2.2%) is above the bottom 25% of dividend payers in the market.

Dividend Stability 1/2

Dividends paid without a cut of more than 10% for 5 years.

Dividend Growth 1/1

Dividends paid grew over the past 5 years.

Payout Ratio 1/1

Payout ratio is 29.0%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Biofarm Bucure stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Biofarm Bucure

Biofarm S.A. manufactures pharmaceutical products. The company's products include cardiovascular, digestive and metabolic, genito-urinary, ophthalmological, endocrine, nervous system, osteo-muscular, respiratory and ENT, multivitamin, antiallergen, and dermatological products. Biofarm S.A. was founded in 1921 and is based in Bucharest, Romania. As of June 24, 2026, Biofarm S.A. operates as a subsidiary of Polpharma SA Pharmaceutical Works.

Full company profile